Market Performance of Neumora Therapeutics (NMRA)
Neumora Therapeutics Inc. (NMRA) experienced a sharp decline of –10.54 % during the 24‑hour trading window that closed at 12:35 PM Central Europe on Friday, 23 March 2026. At the close of that session, a single share of NMRA was valued at approximately USD 0.41 on major exchanges. With a total float of 186.1 million shares, the company’s market capitalisation stood at USD 78.2 million. In the last 24 hours, roughly USD 656.2 thousand of NMRA shares were traded, reflecting modest liquidity amid the recent sell‑off.
Technical Indicators
200‑Day Simple Moving Average (SMA): USD 1.84 The current price is well below the long‑term average, suggesting a sustained bearish trend.
52‑Week High: USD 3.65 (recorded on 18 February 2026)
52‑Week Low: USD 0.32 (recorded on 14 October 2026)
These levels highlight the volatility that has characterised NMRA’s trading activity over the past year.
Recent Performance
Since the end of February, NMRA shares have fallen by –46.6 %, indicating a significant erosion of investor confidence. The sharp drop in the most recent 24‑hour period may be attributed to broader market concerns over the company’s clinical pipeline, regulatory milestones, or competitive dynamics within the neuro‑oncology segment.
Peer Comparison
The following snapshot shows how comparable biopharmaceutical stocks have behaved over the same 24‑hour interval:
| Stock | Ticker | 24‑Hour Move | Current Price | Market Capitalisation |
|---|---|---|---|---|
| Atlantic Sapphire Asa | ASA.OL | 0 % | EUR 0.07 | EUR 82.1 million |
| Airsculpt | AIRS | –1.54 % | USD 1.25 | USD 92.3 million |
| Onkure Therapeutics | OKUR | –2.54 % | USD 2.58 | USD 93.1 million |
| Tonix Holding | TNXP | –5.52 % | USD 5.13 | USD 93.1 million |
| Kewaunee Scientific Corp. | KEQU | –0.03 % | USD 32.38 | USD 92.8 million (P/E = 11.71) |
While most peers have also registered declines, the magnitude of NMRA’s drop is notably larger, underscoring sector‑specific risks or company‑specific catalysts that may have prompted a sharper sell‑off.
About Neumora Therapeutics
Neumora Therapeutics Inc., headquartered in Watertown, United States, is a clinical‑stage biopharmaceutical company focused on the discovery, development, and commercialisation of targeted therapies for brain diseases. The company’s mission is to revolutionise disease management and enhance patient outcomes and quality of life.
